To determine the effects of combined therapy of gliclazide and bedtime insulin on glycemic control and C-peptide secretion, we studied 25 patients with type 2 diabetes and sulfonylurea secondary failure, aged 56.8 +/- 8.3 years, with a duration of diabetes of 10.6 +/- 6.6 years, fasting plasma glucose of 277.3 +/- 64.6 mg/dl and a body mass index of 27.4 +/- 4.8 kg/m2. Patients were submitted t...

*Research Scholar Department of Pharmacy, School of Medical and Allied Sciences Galgotias University, Gautam Buddh Nagar, Greater Noida (U.P.) e-mail: [email protected] Abstract: The objective of the present study was to develop floating microspheres of Gliclazide in order to achieve an extended retention in the upper gastrointestinal tract, which may result in enhanced absorption a...

Abstract Background Cocrystallization is one of the crystal engineering strategies used to alter physicochemical properties drugs that are poorly water-soluble. Gliclazide (GLZ), an antidiabetic drug, belongs Biopharmaceutical Classification System class-II (low solubility and high permeability) has low bioavailability, resulting in poor therapeutic effects patients. Therefore, impart better bi...

Recently, cases of liver injury associated with dipeptidyl peptidase-4 (DPP-4) inhibitors have been reported (1,2). Some postulate the liver injury is mediated by class effect ofDPP-4 inhibitors (1), asDPP4 is identical to CD26 expressed in lymphocytes and macrophages and DPP-4 inhibitors suppress CD26-induced T-cell activation, thereby contributing to immunomodulation (3). However, no report p...